“AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain,” said John Murphy III, president and CEO.
Saves more than $800 million over 10 years; brings lower-cost medicines to patients soone
“AAM and the Biosimilars Council look forward to working with Dr. Oz and his team at CMS to ensure lower-cost medicines are always available for America’s patients.”
“Today's staff reductions may undermine the Agency’s ability to approve and ensure the safety of lower-cost generic and biosimilar medicines.”
The legislation by Reps. Dunn and Mullin aims to cut red tape, expedite generic approvals, and save $800 million over a decade.
The AAM warns that IRA price controls may reduce generics and biosimilars, slowing competition and keeping drug prices high.
President Trump said Monday that he would pause tariffs on Mexico and Canada for a month, but levies on China were still set to take effect on Tuesday.
“It has been an honor to lead our AAM board and I’m excited to continue as chair,” said Keren Haruvi, president of Sandoz North America.
He most recently served as the chief policy officer at the Biotechnology Innovation Organization, where he led BIO’s legal, policy, and international initiatives for the organization’s healthcare portfolio.
